Posted by Michael Wonder on 07 Sep 2017
NeuroRx awarded FDA fast track designation for first drug regimen targeting suicide in bipolar depression
6 September 2017 - NeuroRx has been granted fast track status by the US FDA for its sequential therapy of NRX-100 (ketamine hydrochloride) followed by NRX-101 (D-cycloserine + lurasidone).
The company will shortly begin enrolling patients in a pivotal trial of this sequential therapy targeting patients who are admitted to emergency departments with acute suicidal ideation and behaviour in bipolar depression.
